Abstract

In view of the present situation of China’s biopharmaceutical industry and by analyzing the status quo of supervision in the fields of bio-pharmaceutical registration, production and circulation, this text tries to propose some appropriate measures for improvement. And some conclusions are made that supervision over biopharmaceutical industry must be continually improved; measures should be made by the State Food and Drug Administration to make the biopharmaceutical industry have a sound development.

This work is licensed under a Creative Commons Attribution 4.0 License.